Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Solid Tumor 3Ovarian Neoplasms 3Fallopian Tube Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Injections 6pembrolizumab 5toripalimab 3tislelizumab 3senaparib 3Bevacizumab 3sintilimab 2Technetium 2Specimen Handling 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Carboplatin 2Blood Specimen Collection 2zimberelimab 1tumor-cells apoptosis factor, human 1tazemetostat 1spartalizumab 1sacituzumab govitecan 1rucaparib 1osimertinib 1olaparib 1etoposide phosphate 1enzalutamide 1envafolimab 1cemiplimab 1cedazuridine 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Ultrasonography, Doppler 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Solid Tumor × senaparib × 1 year × Clear all
NCT05390944 2025-09-16

An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition

Impact Therapeutics, Inc.

Phase 1 Completed
28 enrolled
Other solid neoplasm

Solid Tumor

NCT05391048 2025-09-16

An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition

Impact Therapeutics, Inc.

Phase 1 Completed
36 enrolled
Other solid neoplasm

Solid Tumor

NCT07030439 2025-06-22

A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State

Impact Therapeutics, Inc.

Phase 1 Completed
32 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡